111 related articles for article (PubMed ID: 26370910)
1. Pharmacokinetics, Pharmacodynamics, and Efficacy of a Novel Long-Acting Human Growth Hormone: Fc Fusion Protein.
Kim SJ; Kwak HH; Cho SY; Sohn YB; Park SW; Huh R; Kim J; Ko AR; Jin DK
Mol Pharm; 2015 Oct; 12(10):3759-65. PubMed ID: 26370910
[TBL] [Abstract][Full Text] [Related]
2. Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children.
Hou L; Chen ZH; Liu D; Cheng YG; Luo XP
Drug Des Devel Ther; 2016; 10():13-21. PubMed ID: 26719670
[TBL] [Abstract][Full Text] [Related]
3. Development of a sustained-release recombinant human growth hormone formulation.
Kwak HH; Shim WS; Choi MK; Son MK; Kim YJ; Yang HC; Kim TH; Lee GI; Kim BM; Kang SH; Shim CK
J Control Release; 2009 Jul; 137(2):160-5. PubMed ID: 19332090
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human growth hormone (GH)-binding protein enhances the growth-promoting activity of human GH in the rat.
Clark RG; Mortensen DL; Carlsson LM; Spencer SA; McKay P; Mulkerrin M; Moore J; Cunningham BC
Endocrinology; 1996 Oct; 137(10):4308-15. PubMed ID: 8828490
[TBL] [Abstract][Full Text] [Related]
5. Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys.
Osborn BL; Sekut L; Corcoran M; Poortman C; Sturm B; Chen G; Mather D; Lin HL; Parry TJ
Eur J Pharmacol; 2002 Dec; 456(1-3):149-58. PubMed ID: 12450581
[TBL] [Abstract][Full Text] [Related]
6. In Vitro and in Vivo Characterization of MOD-4023, a Long-Acting Carboxy-Terminal Peptide (CTP)-Modified Human Growth Hormone.
Hershkovitz O; Bar-Ilan A; Guy R; Felikman Y; Moschcovich L; Hwa V; Rosenfeld RG; Fima E; Hart G
Mol Pharm; 2016 Feb; 13(2):631-9. PubMed ID: 26713839
[TBL] [Abstract][Full Text] [Related]
7. A novel long-acting human growth hormone fusion protein (VRS-317): enhanced in vivo potency and half-life.
Cleland JL; Geething NC; Moore JA; Rogers BC; Spink BJ; Wang CW; Alters SE; Stemmer WP; Schellenberger V
J Pharm Sci; 2012 Aug; 101(8):2744-54. PubMed ID: 22678811
[TBL] [Abstract][Full Text] [Related]
8. A novel sustained-release formulation of recombinant human growth hormone and its pharmacokinetic, pharmacodynamic and safety profiles.
Wei Y; Wang Y; Kang A; Wang W; Ho SV; Gao J; Ma G; Su Z
Mol Pharm; 2012 Jul; 9(7):2039-48. PubMed ID: 22663348
[TBL] [Abstract][Full Text] [Related]
9. A new animal model for evaluation of long-term growth rate over one month by rhGH/PLGA microcapsule formulations.
Takada S; Kurokawa T; Misaki M; Taira K; Yamagata Y
J Pharm Pharmacol; 2003 Jul; 55(7):951-61. PubMed ID: 12906752
[TBL] [Abstract][Full Text] [Related]
10. A Cell-Based Strategy for Bioactivity Determination of Long-Acting Fc-Fusion Recombinant Human Growth Hormone.
Yao W; Yu L; Fan W; Shi X; Liu L; Li Y; Qin X; Rao C; Wang J
Molecules; 2019 Apr; 24(7):. PubMed ID: 30970583
[TBL] [Abstract][Full Text] [Related]
11. The effect of polyethylene glycol recombinant human growth hormone on growth and glucose metabolism in hypophysectomized rats.
Zhang ZX; Liu YK; Pan H; Pan L; Zhang Q; Su HM; Zhao QL; Li H; He C
Growth Horm IGF Res; 2012 Feb; 22(1):30-5. PubMed ID: 22257554
[TBL] [Abstract][Full Text] [Related]
12. A long-acting pegylated recombinant human growth hormone (Jintrolong
Guan Y; He F; Wu J; Zhao L; Wang X; Huang L; Zeng G; Ren B; Chen J; Liao X; Ma Z; Chen X; Zhong G; Huang M; Zhao X
J Clin Pharm Ther; 2018 Oct; 43(5):640-646. PubMed ID: 29959799
[TBL] [Abstract][Full Text] [Related]
13. A long-acting, mono-PEGylated human growth hormone analog is a potent stimulator of weight gain and bone growth in hypophysectomized rats.
Cox GN; Rosendahl MS; Chlipala EA; Smith DJ; Carlson SJ; Doherty DH
Endocrinology; 2007 Apr; 148(4):1590-7. PubMed ID: 17234711
[TBL] [Abstract][Full Text] [Related]
14. Designing a long-acting human growth hormone (hGH) by fusing the carboxyl-terminal peptide of human chorionic gonadotropin beta-subunit to the coding sequence of hGH.
Fares F; Guy R; Bar-Ilan A; Felikman Y; Fima E
Endocrinology; 2010 Sep; 151(9):4410-7. PubMed ID: 20660071
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic/pharmacodynamic (PK/PD) differentiation of native and PEGylated recombinant human growth hormone (rhGH and PEG-rhGH) in the rat model of osteoarthritis.
Nemirovskiy O; Zheng YJ; Tung D; Korniski B; Settle S; Skepner A; Yates M; Aggarwal P; Sunyer T; Aguiar DJ
Xenobiotica; 2010 Aug; 40(8):586-92. PubMed ID: 20509748
[TBL] [Abstract][Full Text] [Related]
16. Equivalent potency and pharmacokinetics of recombinant human growth hormones with or without an N-terminal methionine.
Moore JA; Rudman CG; MacLachlan NJ; Fuller GB; Burnett B; Frane JW
Endocrinology; 1988 Jun; 122(6):2920-6. PubMed ID: 3371267
[TBL] [Abstract][Full Text] [Related]
17. Differential long-term effects of insulin-like growth factor-I (IGF-I) growth hormone (GH), and IGF-I plus GH on body growth and IGF binding proteins in hypophysectomized rats.
Fielder PJ; Mortensen DL; Mallet P; Carlsson B; Baxter RC; Clark RG
Endocrinology; 1996 May; 137(5):1913-20. PubMed ID: 8612531
[TBL] [Abstract][Full Text] [Related]
18. A pharmacokinetic/pharmacodynamic model for recombinant human growth hormone effects on induction of insulin-like growth factor I in monkeys.
Sun YN; Lee HJ; Almon RR; Jusko WJ
J Pharmacol Exp Ther; 1999 Jun; 289(3):1523-32. PubMed ID: 10336548
[TBL] [Abstract][Full Text] [Related]
19. Single chain Fc-dimer-human growth hormone fusion protein for improved drug delivery.
Zhou L; Wang HY; Tong S; Okamoto CT; Shen WC; Zaro JL
Biomaterials; 2017 Feb; 117():24-31. PubMed ID: 27923197
[TBL] [Abstract][Full Text] [Related]
20. Novel assays based on human growth hormone receptor as alternatives to the rat weight gain bioassay for recombinant human growth hormone.
Roswall EC; Mukku VR; Chen AB; Hoff EH; Chu H; McKay PA; Olson KC; Battersby JE; Gehant RL; Meunier A; Garnick RL
Biologicals; 1996 Mar; 24(1):25-39. PubMed ID: 8733599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
